{
    "organizations": [],
    "uuid": "b8ce372665aa95036c1f935f83b6ffadfc88fe40",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-roche-says-phase-ii-study-shows-po/brief-roche-says-phase-ii-study-shows-potential-for-new-eye-drug-idUSFWN1Q102E",
    "ord_in_thread": 0,
    "title": "BRIEF-Roche says Phase II study shows potential for new eye drug",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - Roche Holding Ag:\n* SAYS PHASE II DATA SUPPORT POTENTIAL FOR ROCHE’S NOVEL ANTI-VEGF/ANTI-ANGIOPOIETIN-2 BISPECIFIC ANTIBODY FOR PEOPLE WITH DIABETIC MACULAR EDEMA‍​\n* SAYS RG7716 DEMONSTRATED CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT IMPROVEMENTS IN VISUAL ACUITY Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)\n ",
    "published": "2018-02-12T14:07:00.000+02:00",
    "crawled": "2018-02-13T15:48:32.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "roche",
        "holding",
        "ag",
        "say",
        "phase",
        "ii",
        "data",
        "support",
        "potential",
        "roche",
        "novel",
        "bispecific",
        "antibody",
        "people",
        "diabetic",
        "macular",
        "say",
        "rg7716",
        "demonstrated",
        "clinically",
        "meaningful",
        "statistically",
        "significant",
        "improvement",
        "visual",
        "acuity",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "zurich",
        "newsroom"
    ]
}